跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 85 条关于
“AbYlink”
全部
85
临床试验
54
药物
9
机构
3
资讯
19
去年
Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceutical Research with AbYlink™ Technology
去年
Baylink Biosciences to Present Novel ADC Platform Data for Cancer Treatment at AACR 2025
去年
Structure Therapeutics Advances Oral Amylin Agonist ACCG-2671 for Obesity Treatment
去年
Amylin Analogs Emerge as Key Players in Next-Generation Obesity Treatments
去年
AbbVie Enters Obesity Market with $350M Gubra Deal for Novel Amylin Analog
2年前
Novo Nordisk's Amycretin Pill Shows Promising 13% Weight Loss in Early Trial
去年
Allink Biotherapeutics Secures $42 Million in Series A Funding to Advance Bispecific Antibody and ADC Pipeline
去年
Senti Bio Announces Promising Early Phase 1 CAR-NK Data, Stock Surges
去年
Metsera's Monthly Amylin Injection Achieves 8.4% Weight Loss in Phase I Trial
去年
AceLink Therapeutics' AL01211 Shows Promising Safety and Biomarker Reduction in Phase 2 Fabry Disease Trial
第 1 页,共 2 页
上一页
下一页